|
INHIBITOR -> TARGET
|
In contrast to approved therapies targeting Class I V600E BRAF mutant tumors, KIN-2787 was active across all classes of BRAF-altered melanoma cells.
|
|
INHIBITOR -> TARGET
|
49.2 NANOMOLAR [46.2 to 52.2] (average)
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
8.2 [6.7 to 9.7] (average)
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
RADIOLIGAND->TARGET
|
A serine/threonine kinase PET
imaging agent for the melanomas mainly in the specific expression of the BRAFV600E mutation.
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
An ATP competitive inhibitor. Binding assay
COMPETITIVE INHIBITOR
|
|
WEAK INHIBITOR->TARGET
|
495 NANOMOLAR [378 to 612] (average)
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
PRECLINICAL
|